Table 1.
Demographic and prognostic factors for vaccinated and observation patients
| Vaccinated, HLA-A2+, A3a (n = 96)a |
Observed, HLA-A2−, A3− (n = 81)b |
P | |
|---|---|---|---|
| Median age, years | 58.9 | 55.1 | |
| Range, years | 32–80 | 34–87 | 0.33 |
| Race | |||
| White % | 89.6 | 81.5 | |
| Other % | 10.4 | 18.5 | 0.12 |
| Tumor size | |||
| T1 % | 69.8 | 60.5 | 0.20 |
| T2–T4 % | 30.2 | 39.5 | 0.20 |
| Histological grade | |||
| I–II % | 64.5 | 59.5 | 0.50 |
| III % | 35.5 | 40.5 | 0.50 |
| Node-positive % | 46.9 | 56.8 | 0.19 |
| Median + nodes (NP only) | 2.0 | 2.5 | |
| Range | 1–25 | 1–15 | 0.17 |
| HER2/neu IHC 3 + or FISH + % | 25.8 | 28.4 | 0.32 |
| Hormone receptor negative % | 31.6 | 17.3 | 0.03 |
| XRT % | 71.9 | 80.2 | 0.20 |
| Chemoprevention % | 65.6 | 78.8 | 0.05 |
| Adjuvant Herceptin % | 5.2 | 3.7 | 0.60 |
a101 patients enrolled to vaccine arm, 2 switched to observation, 1 withdrew for adjuvant trastuzumab, 1 due to an extended unrelated illness, and 1 patient for personal reasons
b85 patients enrolled to observation arm, 2 lost to follow-up and 4 withdrew to another vaccine trial. Two patients were gained from the vaccine arm [27]